1. Home
  2. MRKR vs LSH Comparison

MRKR vs LSH Comparison

Compare MRKR & LSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • LSH
  • Stock Information
  • Founded
  • MRKR N/A
  • LSH 2018
  • Country
  • MRKR United States
  • LSH United States
  • Employees
  • MRKR N/A
  • LSH N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • LSH
  • Sector
  • MRKR Health Care
  • LSH
  • Exchange
  • MRKR Nasdaq
  • LSH NYSE
  • Market Cap
  • MRKR 21.9M
  • LSH 20.3M
  • IPO Year
  • MRKR N/A
  • LSH 2024
  • Fundamental
  • Price
  • MRKR $2.16
  • LSH $1.92
  • Analyst Decision
  • MRKR Strong Buy
  • LSH
  • Analyst Count
  • MRKR 1
  • LSH 0
  • Target Price
  • MRKR $19.00
  • LSH N/A
  • AVG Volume (30 Days)
  • MRKR 53.9K
  • LSH 78.2K
  • Earning Date
  • MRKR 11-14-2024
  • LSH 02-01-2025
  • Dividend Yield
  • MRKR N/A
  • LSH N/A
  • EPS Growth
  • MRKR N/A
  • LSH N/A
  • EPS
  • MRKR N/A
  • LSH N/A
  • Revenue
  • MRKR $5,395,849.00
  • LSH $18,248,233.00
  • Revenue This Year
  • MRKR $64.48
  • LSH N/A
  • Revenue Next Year
  • MRKR N/A
  • LSH N/A
  • P/E Ratio
  • MRKR N/A
  • LSH N/A
  • Revenue Growth
  • MRKR 79.04
  • LSH 28.38
  • 52 Week Low
  • MRKR $1.83
  • LSH $1.78
  • 52 Week High
  • MRKR $5.99
  • LSH $5.37
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 32.84
  • LSH N/A
  • Support Level
  • MRKR $1.83
  • LSH N/A
  • Resistance Level
  • MRKR $2.79
  • LSH N/A
  • Average True Range (ATR)
  • MRKR 0.28
  • LSH 0.00
  • MACD
  • MRKR -0.09
  • LSH 0.00
  • Stochastic Oscillator
  • MRKR 21.02
  • LSH 0.00

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About LSH LAKESIDE HOLDING LTD

Lakeside Holding Ltd i an integrated cross-border supply chain solution provider with a strategic focus on the Asian market including China and South Korea. It provides customized cross-border ocean freight solutions and airfreight solutions in the U.S, including cross-border freight consolidation and forwarding services; customs clearance services; warehousing and distribution services and U.S. domestic ground transportation services.

Share on Social Networks: